stockrowInhibikase Therapeutics, Inc. (IKT) vs Protalix BioTherapeutics, Inc. (PLX)
- Inhibikase Therapeutics, Inc. IKT 1.50 +4.17%
- Protalix BioTherapeutics, Inc. PLX 2.54 +1.20%
Inhibikase Therapeutics, Inc. and Protalix BioTherapeutics, Inc. are both Biotechnology companies. Inhibikase Therapeutics, Inc. and Protalix BioTherapeutics, Inc. are of similar size ($209.3M and $204.7M). Inhibikase Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Protalix BioTherapeutics, Inc. trades at 10.6×. Inhibikase Therapeutics, Inc. grew revenue faster over the last twelve months: 110.9% against 30.1%. Protalix BioTherapeutics, Inc. has the higher net margin (23.5% vs 0.00%) and the higher return on invested capital (48.5% vs 0.00%). Across the 17 metrics below, Protalix BioTherapeutics, Inc. leads on 11 and Inhibikase Therapeutics, Inc. on 6.
Valuation
Profitability
| Metric | IKT | PLX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 69.20% | 68.51% |
| Operating margin | 0.00% | 28.89% | 0.00% |
| Net margin | 0.00% | 23.50% | 0.00% |
| Free cash flow margin | 0.00% | 9.51% | 0.00% |
| Return on equity | (51.96%) | 31.23% | (51.96%) |
| Return on assets | (48.04%) | 20.07% | (46.06%) |
| Return on invested capital | 0.00% | 48.48% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack